Service

Corporate Communications

For Investors

Phone worldwide: +49 2103 29 11711
Phone U.S.: +1 240 686 2222
Email: IR@QIAGEN.COM

For Media

Phone worldwide: +49 2103 29 11826
Phone U.S.: +1 240 686 7425
Email: PR@QIAGEN.COM

QIAGEN on the web

www.QIAGEN.com
www.corporate.QIAGEN.com
www.facebook.com/QIAGEN
www.twitter.com/QIAGEN
www.linkedin.com/company/QIAGEN
www.youtube.com/QIAGEN
www.instagram.com/qiagen

Financial Calendar

Annual General Meeting of Shareholders of QIAGEN N.V.

June 2021

Second Quarter 2021 Results

July 2021

Third Quarter 2021 Results

November 2021

Fourth Quarter 2021 Results (provisional)

February 2021

Publication Date

May 2021

Trademarks

Our name together with our logo is registered as a trademark in the United States and a number of other countries: QIAGEN^®.

For a complete list of QIAGEN’s trademarks and disclaimers, please refer to QIAGEN’s webpage under www.QIAGEN.com/trademarks_disclaimers.aspx.

As of February 2021, QIAGEN molecular diagnostics products included 24 FDA (PMA-approved or 510 (k)-cleared) products, 18 clinical sample concentrator products (14 kits and 4 instruments) 60 EU CE IVD assays, 17 EU CE IVD sample preparation products, 18 EU CE IVD instruments for sample purification or detection, 34 China CFDA IVD assays/sample preparations and 9 China CFDA IVD instruments.

This Annual Report may also contain trade names or trademarks of companies other than QIAGEN.

This document contains detailed financial information about QIAGEN prepared under generally accepted accounting standards in the U.S. (U.S. GAAP) and included in our Form 20-F annual report filed with the U.S. Securities and Exchange Commission. QIAGEN also publishes an Annual Report under IFRS accounting standards, which is available on our website at www.QIAGEN.com.